anticancer agent 15

Anticancer agent 15, an anticancer agent, exerts its efficacy by elevating intracellular levels of reactive oxygen species (ROS) and inducing cell death in melanoma cancer cells through necroptosis.

Anticancer agent 3 (Compound 4) is an anticancer agent.

Anticancer Agent 157 (compound 15) is a nitric oxide (NO) inhibitor with IC50 values of 0.62 μg/mL, exhibiting both anti-inflammatory and anticancer effects. It interacts with inducible NO synthase (iNOS) and caspase 8, which facilitates apoptosis through nuclear fragmentation and chromatin condensation. Additionally, Anticancer Agent 157 effectively inhibits HT29 colon cancer cells (IC50 =2.45 μg/mL), Hep-G2 liver cancer cells (IC50 =3.25 μg/mL), and B16-F10 murine melanoma cells (IC50 =3.84 μg/mL) [1].

Antiproliferative agent-15 is a reagent with anticancer activity. Antiproliferative agent-15 showed antiproliferative activity against human colon cancer (HCT116 and HCT15) and brain cancer (LN-229 and GBM-10).

Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) and binds to Heat shock protein 90 (Hsp90) with a dissociation constant (Kd) of 3.86 μM, demonstrating its apoptosis-inducing capabilities [1].

Anticancer Agent 108 (Compound 3.10) serves as a potent P-gp inhibitor exhibiting considerable antitumor properties while maintaining reduced toxicity to both normal and pseudonormal cells; it also demonstrated no acute toxic effects on C57BL/6 mice [1].

Anticancer Agent 110 exhibits potent in vitro anti-leukemia activity, demonstrating high cytotoxicity against K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. It induces DNA damage and subsequently triggers apoptosis [1].

Anticancer Agent 146 (Compound 1.19) acts as a necroptosis inducer and demonstrates anti-tumor efficacy in the MDA-MB-231 mouse xenograft model [1].

Anticancer Agent 153 (Compound 3) promotes apoptosis through the generation of Reactive Oxygen Species (ROS) and elevates the loss of Mitochondrial Membrane Potential (MMP), effectively inhibiting cancer cell proliferation [1].

Antioxidant agent-15 (Compound 4) demonstrates potent antioxidant inhibition activity with an IC50 value of 15.44 nM, and effectively inhibits tumor cell growth in Hela, Hep G2, and Caco-2 cells, with respective IC50 values of 395.26 nM, 400.4 nM, and 24.6 nM [1].

Antimalarial agent 15 is a parasite inhibitor that exhibits antimalarial effects and inhibits the growth of Plasmodium falciparum 3D7 with an IC50 value of 20 nM.

Anticancer agent 49 (compound 69) is a broad-spectrum anticancer agent with anti-proliferative activity. Anticancer agent 48 inhibits microtubule protein aggregation and has in vivo antitumour activity, with potential for studies on solid tumours and haematological tumours.

Anticancer agent 32 (compound 2g) is an anticancer compound that affects the cell cycle and induces apoptosis, making it valuable for cancer research.

Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].

Anticancer agent 59, an inhibitor active against various cancer cell lines, particularly demonstrates efficacy in A549 cells with an IC 50 value of 0.2 μM. It prompts apoptosis, elevates Ca2+ and ROS levels within cancer cells, and markedly reduces mitochondrial membrane potential. Additionally, it effectively curtails tumor growth in the A549 mouse xenograft model.

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

Anticancer Agent 102, a tetracaine derivative, exhibits anti-cancer activity by inducing apoptosis [1].

Anticancer agent 81 (Compound 37b3) induces tumor cell cycle arrest and apoptosis, and serves as a payload for conjugation with Trastuzumab, forming the antibody-drug conjugate (ADC) T-PBA, which retains Trastuzumab's targeting and internalization properties [1].

Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0/G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].

Anticancer agent 29 (Compd E Z-6f) exhibits potent anticancer activity with IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, and 0.396 μM for CDK2, CDK1, CDK4, and CDK6, respectively [1].

Anticancer agent 38 (compound 19) is an aryl-urea compound, and is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC 50 of 5.2 μg/mL [1].

Anticancer agent 54 is an effective anticancer agent whose anticancer activity depends on DNA embedding and ROS generation. Anticancer agent 54 has an anti-proliferative effect by blocking the cell cycle in G0/G1 phase and inducing apoptosis.

Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticancer agent 57 effectively inhibits tumor growth. Consequently, Anticancer agent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1].

Compound 6i, an anticancer agent, exhibits promising activity against breast adenocarcinoma [1].

Compound 3a, an anticancer agent and ketone derivative, exhibits potent activity against the A549 cancer cell line, demonstrating an inhibitory concentration (IC50) of 6.62 μM [1].

Compound 166, also referred to as compound 3, exhibits potent anticancer properties, demonstrating significant inhibitory activity against Caco-2 cells with an IC50 value of 9.6 nM [1].

Anticancer agent 160 (Compound 6), a natural product extracted from Parthenium hysterophorus, exhibits cytotoxicity against HCT-116 cells with an IC50 of 5.0 μM [1].

Anticancer agent 112[1], serves as a potent agent for cancer research.

Compound 103 (Compound 2k) serves as a potent anticancer agent [1].

Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida albicans (MIC: 0.039-0.156 mg/ml). Anticancer agent 34 inhibited the growth of A549 cells (IC50: 8.4 μg/ml), PC3 cells (IC50: 7.8 μg/ml).

Anticancer agent 79 (compound 3d) is an anticancer compound with good anti-breast cancer activity, exhibiting cytotoxic activity in T47-D cells (IC50= 13.64 ± 0.26 μM).

Anticancer agent 40 (compound 3e) is a potent anticancer agent with effects on SKBR-3 cells (IC50: 0.94 nM), SKOV-3 cells (IC50: 0.98 nM), PC-3 cells (IC50: 0.96 nM), U-87 cells (IC50: 0.95 nM), and HDF cells (IC50: 2.13 nM).

Anticancer agent 30 (compound 6f-Z) is a potent 3-arylidene-2-oxindole derivative that acts as a selective CDK2 inhibitor, showing significant anticancer activity and potential as a cancer treatment [1].

Anticancer agent 50 (compound 6), a potent modulator of the ABCB1 efflux pump, exhibits cytotoxic and anti-proliferative activity by reducing cyclin D1 expression and inducing p53 expression. It shows significant potential for research in T lymphoma.

Compound 6h (Anticancer Agent 139) exhibits potent anticancer activity, engaging in a π-cationic interaction with Lys352 of Tubulin and demonstrating high efficacy against SNB-19, OVCAR-8, and NCI-H460 with PGIs of 86.61, 85.26, and 75.99, respectively. Moreover, it shows moderate activity against a range of other cancer cell lines — HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 — with PGIs between 51.88 and 67.55 [1].

Anticancer Agent 118, an N‑acylated ciprofloxacin derivative, exhibits antibacterial efficacy against Gram-positive strains and antiproliferative effects on prostate PC3 cells, making it a potential candidate for antitumor research [1].

Antitrypanosomal Agent 15 (Compound 26) is an orally active, brain-penetrant, selective inhibitor of the Trypanosoma cruzi proteasome, exhibiting a pIC50 of 7.4 for T. cruzi and <4 for the human proteasome. It possesses favorable ADME properties, rendering it useful for the study of Chagas disease [1].

Compound 140 (Compd 3) exhibits potential anticancer and antiparasitic activities [1].

Anticancer agent 137 (8q), a potent PI3k inhibitor, exhibits broad-spectrum anticancer activity by inducing G2/M cell cycle arrest and apoptosis. It increases levels of cleaved PARP, and caspases 3 and 7, making it useful in cancer research [1].

Anticancer Agent 143 (Compound 369), a potent dual inhibitor targeting PTPN2 and PTP1B, exhibits IC50 values below 2.5 nM. It is employed in cancer research [1].

Anticancer agent 80 (Compound 3c) exhibits a significant dark toxic effect on T47-D cells, with an IC50 of 10.14 μM.

Anticancer agent 61 is an orally active anticancer agent. anticancer agent 61 was able to inhibit the proliferation of HepG2, Bel-7402 and MCF-7 cancer cells with IC50 values of 1.12, 1.97 and 1.08 μM respectively. anticancer agent 61 inhibited tumour Anticancer agent 61 was able to inhibit tumour growth.

Anticancer agent 92 is an anticancer agent that is nontoxic against noncancerous cells .

Compound 12, also known as Anticancer agent 68, functions as an anti-cancer agent by arresting cells at the G2/M phase and inducing programmed cell death. Moreover, it promotes tumor suppression by activating p53 and PTEN [1].

Anticancer agent 65 showed good results in tumour cell lines, especially A549 cells (IC50: 1.07 μM). anticancer agent 65 blocked the cell cycle of A549 cells in S phase, induced apoptosis, increased the expression of p53 and p21, and contributed to ROS generation and MMP collapse.

Antitubercular agent-15 (Compound 5n) is an antitubercular agent with low cytotoxicity against pulmonary fibroblasts and macrophages. The MIC90 values against M. tuberculosis H37Rv, CF16, CF61, CF76, CF152, and CF161 are 0.73, 7.69, 9.38, 18.80, 7.53, and 7.31 μg mL, respectively [1].

Antifungal agent 15 exhibits remarkable potency, with EC50 values of 0.52 and 0.50 μg/mL against S. sclerotiorum and B. cinerea, respectively.